NCT03183739View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 20, 2017

Primary Completion Date

October 6, 2017

Study Completion Date

October 6, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

ASP8062

ASP8062 will be administered orally.

DRUG

Placebo

Placebo will be administered orally.

Trial Locations (1)

Unknown

Site JP00001, Sumida City

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY